Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02625935 · ClinicalTrials.gov registry record
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients
A clinical trial of Breast Cancer, sponsored by NanoString Technologies.
- Completed
- Registry status
- 206
- Enrollment target
- 4
- Study locations
NCT02625935: Completed study of Breast Cancer, sponsored by NanoString Technologies.
NCT02625935 is a study of Breast Cancer that has completed, run by NanoString Technologies. The registered enrollment target is 206 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02625935, a study of Breast Cancer, has completed, sponsored by NanoString Technologies.
- COMPLETED
- Registry status
- 206 participants
- Enrollment target
- 4
- Study locations
Study Summary
This multicenter, prospectively designed study examines whether the Prosigna score influences physician and patient adjuvant treatment selection over and above currently used prognostic factors. This study also examines the impact of the test results on patients' reported outcomes, including their decisional conflict status and anxiety levels.
Conditions Studied
Study Locations (4)
Florida
- Florida Cancer Center - Fort Myers
Maine
- New England Cancer Specialists - Scarborough
Maryland
- Center for Cancer and Blood Disorders - Bethesda
New York
- North Shore Hematology Oncology Assoaciates - East Setauket
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-10-10 |
What the finished NCT02625935 record still lists
NCT02625935 is an observational study that tracks outcomes without assigning an intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02625935 reports a single indexed study location in Florida, Maine, Maryland.
Frequently Asked Questions
What is clinical trial NCT02625935 about?
NCT02625935 is a clinical study titled "Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients". This multicenter, prospectively designed study examines whether the Prosigna score influences physician and patient adjuvant treatment selection over and above currently used prognostic factors. This study also examines the impact of the test results on patients' reported outcomes, including their d...
What is the current status of trial NCT02625935?
This trial is currently completed. The enrollment target is 206 participants. The study started on 2015-12. Estimated completion is 2017-10-10.
What conditions does trial NCT02625935 study?
This clinical trial studies the following conditions: Breast Cancer.
Who is sponsoring clinical trial NCT02625935?
This trial is sponsored by NanoString Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02625935 being conducted?
This trial has 4 study locations across Florida, Maine, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02625935's enrollment target sits among peer trials
206 356th of 1224 higher than 869 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia